MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
Portfolio Pulse from Benzinga Newsdesk
MediciNova, a biopharmaceutical company listed on NASDAQ (MNOV), has received a Notice of Intention to Grant from the European Patent Office for a pending patent application. The patent covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
August 17, 2023 | 8:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MediciNova's receipt of the Notice of Intention to Grant for a new patent covering MN-166 could potentially boost the company's market position and stock value.
The granting of a new patent for MN-166 strengthens MediciNova's intellectual property portfolio and could potentially lead to increased revenues from the treatment of macular injury associated with progressive multiple sclerosis. This could positively impact the company's stock value in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100